What is it about?
in the current scenario, use of GP2b/3a is restricted to specific scenarios after advent of potent P2Y12 inhibitors. We evaluated the role of tirofiban in a small group of NSTE-ACS patients who were maanged conservatively in a non PCI capable centre.
Featured Image
Why is it important?
The lack of widepsread health insurance coverage and avaliablity of PCI capable centers leads to many patients of ACS being managed conservatively.In this scenario, tirofiban has shown decrease in refeactory ischemia and reinfarction without increase in risk of bleeding.
Perspectives
The study rekindles interest in the use of GP2b/3a in conservatively managed NSTE-ACS patients.
Dr. Akshyaya Pradhan
King George's Medical University
Read the Original
This page is a summary of: A comparative study of tirofiban plus enoxaparin versus enoxaparin alone along with dual antiplatelet blockade in the management of patients with non-ST elevation acute coronary syndrome, Heart India, January 2018, Medknow,
DOI: 10.4103/heartindia.heartindia_32_18.
You can read the full text:
Contributors
The following have contributed to this page
